Diagnostic Approach for Suspected Adrenal Tumor

Initial Evaluation

• The American Urological Association recommends that all patients with suspected adrenal tumors require both comprehensive hormonal evaluation and cross-sectional imaging with unenhanced CT as the first-line diagnostic approach 1, 2
• Complete hormonal screening must be performed before any surgical intervention, regardless of tumor appearance on imaging, as radiological characteristics cannot reliably predict hormone secretion status 2

Hormonal Evaluation

• The Endocrine Society recommends cortisol excess screening using 1 mg overnight dexamethasone suppression test as the preferred screening method 1, 2
• Basal plasma ACTH levels, 24-hour urinary free cortisol, and basal serum cortisol are also recommended for cortisol excess screening 3
• Aldosterone-to-renin ratio is recommended for aldosterone excess screening if hypertension and/or hypokalemia are present 1, 2
• Plasma free metanephrines are the preferred test for catecholamine excess screening 3, 4, 5

Imaging Evaluation

• Unenhanced CT of the abdomen is the mandatory first imaging study for all adrenal masses, providing critical diagnostic information 6, 1
• Hounsfield units (HU) <10 strongly suggest benign adenoma, while HU >10 require further evaluation with second-line imaging or functional imaging 6, 4, 1
• Chest CT should be obtained concurrently to evaluate for metastatic disease 3, 4

Advanced Functional Imaging

• FDG-PET is indicated for radiologically indeterminate lesions after second-line imaging, suspected adrenocortical carcinoma, and established pheochromocytoma 6, 4, 7
• MIBG scintigraphy, DOTA-TATE-PET, and Dopa/Dopamine PET are additional functional imaging options for pheochromocytoma 3, 4

Critical Diagnostic Pitfalls to Avoid

• Never perform fine needle biopsy of a suspected adrenal tumor before excluding pheochromocytoma biochemically to avoid triggering fatal hypertensive crisis 6, 8, 7, 5
• Do not skip hormonal evaluation even in apparently "benign-appearing" tumors on imaging, as subtle hormone production impacts surgical management and perioperative care 2

Special Considerations for Specific Tumor Types

• For suspected adrenocortical carcinoma, bone scintigraphy and FDG-PET are optional but useful, and pathological diagnosis requires an experienced pathologist using the Weiss score 3, 6, 8
• For confirmed pheochromocytoma, extend imaging to chest and neck if initial abdominal imaging is negative but biochemistry is positive, and consider genetic testing and lifelong surveillance due to malignancy risk 7, 5, 9

Pheochromocytoma‑Related Headache: Diagnosis and Management

Clinical Presentation

• Headaches that begin after the detection of an adrenal tumor strongly suggest a secondary, catecholamine‑induced headache rather than a primary primary headache disorder. 10
• Unilateral periorbital pain that migrates from a retronasal origin is characteristic of the vascular headache pattern seen in catecholamine excess states such as pheochromocytoma. 11
• The majority of patients with pheochromocytoma experience headaches due to chronic catecholamine hypersecretion. 10

Biochemical Evaluation

• Plasma free metanephrines or 24‑hour urinary fractionated metanephrines are the preferred initial tests to confirm or exclude catecholamine excess in patients with an adrenal mass and headache. 10

Procedural Precautions

• Fine‑needle biopsy of an adrenal mass must be avoided until pheochromocytoma has been biochemically excluded, because the procedure can trigger a life‑threatening hypertensive crisis. 12

Imaging Strategies

• For biochemically confirmed pheochromocytoma, ^18F‑FDG PET is superior to ^123I‑MIBG scintigraphy for detecting malignant disease, especially in tumors harboring SDHB mutations. [12][13]

Pre‑operative Management

• A regimen of alpha‑adrenergic blockade for 10–14 days is mandatory before any surgical intervention for pheochromocytoma to prevent intra‑operative hypertensive emergencies. [10][11]

Genetic Considerations

• Approximately 35 % of pheochromocytomas are hereditary; therefore, genetic testing should be offered to all patients with a confirmed diagnosis. 13
• SDHB gene mutations are associated with a higher risk of malignancy and influence both imaging choice (favoring FDG‑PET) and long‑term surveillance protocols. [12][13]

Differential Diagnosis: Migraine

• In pediatric populations, migraineurs may display cranial autonomic symptoms (e.g., nasal congestion) in about 62 % of cases, which can overlap with autonomic features of pheochromocytoma‑related headache but lacks the temporal link to adrenal tumor development. 14
• Typical migraine attacks are longer in duration and are accompanied by photophobia and nausea, distinguishing them from the brief, catecholamine‑triggered headaches of pheochromocytoma. 15

Evidence‑Based Management of Adrenal Tumors

Diagnostic Imaging Criteria

• Adrenal masses larger than 4 cm are associated with a markedly higher risk of malignancy and therefore require an aggressive diagnostic work‑up. 16
• For lesions with HU < 10 (suggesting benign adenoma), a repeat unenhanced CT after 12 months is recommended to monitor for interval growth. 16
• In the same low‑HU lesions, annual hormonal testing for four years is advised to detect any emerging functional activity. 16

Assessment of Indeterminate or Large Lesions

• Lesions with HU > 10 or size > 4 cm should undergo second‑line or functional imaging (e.g., FDG‑PET) to better characterize malignancy risk. 16
• Management decisions for these indeterminate lesions should involve a multidisciplinary team to integrate imaging, hormonal, and clinical data. 16

Features Defining Obvious Malignancy

• Imaging findings that strongly suggest malignancy include size > 4 cm, heterogeneous attenuation, evidence of local invasion, or necrosis. 16

Surgical Approach Recommendations

• When malignancy is evident and the patient is a suitable surgical candidate, an open adrenalectomy is the preferred operative technique. 16
• For masses > 5 cm consistent with adrenocortical carcinoma, an open approach (not minimally invasive) is strongly recommended because minimally invasive surgery is linked to significantly higher recurrence rates. 16

Pre‑operative Management of Pheochromocytoma

• Alpha‑adrenergic blockade must be instituted for 1–3 weeks (minimum 10–14 days) before tumor resection to prevent intra‑operative catecholamine crises. 16
• Beta‑blockers should not be started before adequate alpha‑blockade; they may be added after alpha‑blockade to control reflex tachycardia. 16

Management of Symptomatic Hormone‑Secreting Tumors

• Immediate surgical excision is indicated for any adrenal tumor that is causing clinically significant hormone excess. 16

Biopsy Guidelines

• All major adrenal‑tumor guidelines agree that fine‑needle biopsy must be avoided until pheochromocytoma has been biochemically excluded, as biopsy can precipitate a hypertensive emergency. 16
• Biopsy is reserved only for rare scenarios: (1) a hormonally inactive mass with non‑benign imaging where pathology would directly alter management, or (2) staging of metastatic disease in patients with a known extra‑adrenal primary malignancy. 16

Adrenocortical Carcinoma Hormonal Profile

• Approximately 50 % of adrenocortical carcinomas secrete cortisol, a feature that aids in their diagnosis. 16

Surveillance of Hereditary Pheochromocytoma

• Recurrence rates for hereditary pheochromocytoma are estimated at ≈ 10 % in the original adrenal gland and up to 30 % in the contralateral gland. 16
• Lifelong monitoring is required for patients with hereditary pheochromocytoma to detect recurrences early. 16